EDMONTON, June 6 /CNW/ - Isotechnika Inc. announced today that the Company received approval from the Polish Competent Authority for participation in the ongoing Phase 3 European/Canadian clinical trial. This trial investigates the use of ISA247 in patients suffering from moderate to severe psoriasis. The Company previously received approval from the German Competent Authority and Health Canada to commence the trial. At present, a total of 283 patients have been enrolled in Germany and Canada.
